Kornimate/medical-research-clean huggingface dataset:
long term impact of covid-19

Conditions: Long COVID-19; Post-COVID-19 Syndrome; COVID-19

Summary: covid-19, caused by the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection, has a devastating effect on human lives, including over 6.6 million death as of november 2022. furthermore, many individuals continue to experience persisting sequelae after the initial infection. little is known about the impact of undergoing covid-19 hospitalisation. hence, the investigators propose an observational longitudinal study in a cohort of covid-19 survivors after hospital discharge, to examine their perspectives on their health, health-related quality of life, and persistence of common covid-19 symptoms, such as fatigue, dyspnoea and anxiety. potential influencing socio-demographic and biological factors will additionally assessed.


Eligibility criteria:
inclusion criteria: * ages ≥18 years * pcr-confirmed sars-cov-2 infection and hospital admission * proficiency in dutch * providing informed consent exclusion criteria: - none
pulmonary and upper limb functions in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy; Upper Limb Function; Respiratory Function Test

Summary: although it is known that the functions of pulmonary and upper limb is affected in late stage of duchenne muscular dystrophy (dmd) negatively, the investigators do not have clear information about its early stage. the aim of this study was to investigate the differences in pulmonary and upper limb functions between children with dmd in early stage and healthy peers.


Eligibility criteria:
inclusion criteria: children with dmd was; * age between 5-10 years * being on treatment with corticosteroids for more than 6 months * being at level i according to brooke upper and lower extremity classification systems healthy peers; * age between 5-10 years * not having any diagnosed disease exclusion criteria: • children has undergo surgery and disease affect upper extremity or pulmonary function in last six months.
control of hidradenitis suppurativa of the underarms after combination deroofing and laser

Conditions: Hidradenitis Suppurativa

Summary: the purpose of the study is to determine whether a series of laser hair removal treatments can improve participant outcomes after deroofing procedures. a deroofing procedure is a surgery where larger hidradenitis suppurativa bumps (called nodules) and hidradenitis suppurativa tunnels (called sinus tracts) are removed and left to heal open without stitches.

hidradenitis suppurativa (hs) is a chronic inflammatory disorder characterized by follicular occlusion and rupture which leads to scar and sinus tract formation. given that medical treatments for hs primarily target inflammation, a multifaceted approach to therapy incorporating procedural techniques is thought to lead to better disease control. deroofing of nodules and sinus tracts has shown to be beneficial in the treatment of recalcitrant areas that do not respond fully to medical therapy alone. in addition, multiple studies demonstrate the efficacy of long-pulsed 1064-nm nd:yag laser in the treatment of hs. to date, no study has evaluated the efficacy of combining surgical deroofing and laser treatment. in this study, participants with hurley stage ii disease of bilateral axillae who meet the study criteria will be treated. deroofing will be performed to all nodules and sinus tracts in a randomly selected axilla of each participant. immediately prior to deroofing, participants will have their initial nd:yag laser treatment to the selected axilla. participants will then be treated every four weeks with a series of additional laser treatments. the opposite (untreated) axilla will serve as a control for monitoring baseline disease activity.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of hidradenitis suppurativa hurley stage ii with bilateral axillary involvement * must be under the care of a board certified dermatologist and planning to undergo a deroofing procedure of one axilla for the treatment of their hs * disease must be active in the bilateral axillae * activity to be defined as having had at least one flare in the last six months * flare to be defined as patient reported worsening of disease beyond baseline or clinical evidence of active inflammation (i.e. erythema, edema, drainage, tenderness) exclusion criteria: * pregnancy * clinical evidence of active superinfection * previous deroofing surgery in any axilla * previous laser therapy in any axilla * patients on the following medical therapies: * any systemic immunomodulating agent that has been started within 3 months of initial deroofing and laser treatment * patients on immunomodulators \>3 months with no change in therapy are eligible for participation * use of topical antibiotics, antiseptics, oral antibiotics, oral steroids, intralesional steroids * patients must have stopped all of these agents at least 2 weeks prior to surgical deroofing * use of intramuscular steroids * it must be at least 4 weeks since administration of intramuscular steroids before deroofing for a patient to be eligible for participation
clinical trial of stn-dbs for primary cranial-cervical dystonia

Conditions: Dystonia

Summary: primary cranial-cervical dystonia is managed mainly by repeated botulinum toxin injections.this study is to establish whether subthalamic nucleus neurostimulation could improve symptoms in patients not adequately responding to chemodenervation or oral drug treatment. investigators compared this surgical treatment with sham stimulation in a randomized, controlled clinical trial.

in this randomised, sham-controlled trial, investigators will recruit forty patients with primary cranial-cervical dystonia to receive an implanted device for stn-dbs, and participants will be randomly assigned to receive either neurostimulation or sham stimulation for 3 months.the primary end point was the change from baseline to 3 months in the severity of symptoms, according to the burke-fahn-marsden dystonia rating scale. two masked dystonia experts who unaware of treatment status will assess the severity of dystonia by reviewing standardised videos.subsequently, all patients will receive open-label neurostimulation; blinded assessment will be repeated after 6 months of active treatment.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of primary cranial-cervical dystonia: blepharospasm combined with dystonia of the lower facial muscles. cervical muscles can be involved but did not dominate the clinical picture. 2. medical intractable：including various drugs and local botulinum toxin injections. 3. patients deteriorated in activities of daily living and showed social withdrawal during the course of their disease as they suffered from apparent hyperkinesia of facial muscles and functional blindness secondary to severe blepharospasm. exclusion criteria: 1. all other topographical areas remained unaffected. 2. secondary causes will be excluded by standard cranial magnetic resonance imaging (mri) scans. 3. cognitive impairment, dementia,severe psychiatric diseases as well as higher surgical risks due to comorbidities will also be exclusion criteria.

Keywords: deep brain stimulation subthalamic nucleus dystonia
neural mechanisms of muscle control in individuals with knee pain

Conditions: Patellofemoral Pain Syndrome

Summary: this is a randomized controlled trial of knee muscle versus hip muscle strengthening for patellofemoral pain syndrome.

rationale: two prior randomized controlled trials (rct) have highlighted the importance of hip muscle activation and strengthening as a treatment strategy for patellofemoral pain (khayambashi, 2014; khayambashi, 2012). here, we propose a pilot study to acquire preliminary data to power a larger study to reveal the neural mechanism underlying the effectiveness of this intervention to promote its evidence-based incorporation into clinical practice. intervention: 4 weeks of quadriceps muscle versus 4 weeks of hip strengthening exercises. purpose: to determine changes in brain functional connectivity related to pain reduction induced by the strengthening exercises. study population: males and females with a history of unilateral knee pain. methodology: functional magnetic resonance imaging (fmri) will be used to quantify functional connectivity of brain regions related to hip muscle activation. functional connectivity will be quantified before (pre) and after (post) 4 weeks of quadricep or hip muscle strengthening exercises. arms: as above, there are 2 arms. 4 weeks of quadriceps strengthening exercises (arm 1) versus 4 weeks of hip strengthening exercises (arm 2). outcomes: at the pre and post-intervention sessions in each participant, we will quantify the brain functional connectivity between hip muscle motor cortex and the 1) thalamus, 2) basal ganglia, and 3) insula, and 4) the periaqueductal gray. we will also quantify self-report of pain and biomechanical function of the knee and hip. follow-up: a six month follow-up is planned for this pilot study. analysis plan and statistics: functional connectivity of hip muscle motor cortex will be extracted using standard statistical software for brain mapping. a repeated measures anova will be used to assess change in functional connectivity in the hip and knee group. pain decreases in the both groups will be quantified and reported.

Eligibility criteria:
inclusion criteria: 1. pain located specifically around the patellofemoral articulation (vague or localized). 2. readily reproducible pain (3 out of 10 on a visual analog scale) with at least 2 of the following functional activities commonly associated with pfp: stair ascent or descent, squatting, kneeling, prolonged sitting, or isometric quadriceps contraction. 3. reports of pain greater than 3 months duration. exclusion criteria: 1. previous history of knee surgery. 2. history of traumatic patellar dislocation. 3. neurological involvement that would influence gait. 4. contraindications to mr imaging: implanted electronic devices (i.e. pacemaker), or metallic implants (i.e. aneurysm clips, fixation screws).
an open-label clinical study to evaluate the efficacy of a face cream and eye cream

Conditions: Wrinkle; Photoaging; Fine Lines

Summary: this single-center clinical trial is being conducted to assess the efficacy and tolerability of an anti-aging eye cream and face moisturizer when used over the course of 12 weeks twice-daily by women, 35-65 years, with mild to moderate droopy eyelids, moderate crow's feet wrinkles, and moderate global facial photodamage.

this was an institutional review board (irb)-approved study. female subjects, 35-65 years of age, fitzpatrick skin type i-vi, with mild to moderate droopy eyelids, moderate crow's feet wrinkles, and moderate global photodamage were recruited. subjects applied a multi-ingredient anti-aging face moisturizer and eye twice-daily for 12 weeks. subjects were provided with a gentle cleansing lotion and a sunscreen spf 40+ to be utilized during the course of the study. clinical grading of efficacy and tolerability parameters, visia-cr imaging, raking light visia analysis, skin ph, tewameter, and pinch recoil measurements were performed at baseline, weeks 4, 8, and 12. optical coherence tomography (oct) imaging was performed at baseline and week 12. a total of 42 subjects completed the study.

Eligibility criteria:
inclusion criteria: * women between the ages of 35 and 65 years * women with fitzpatrick skin type i-vi * subjects must have mild to droopy eyelids, moderate crow's feet wrinkles, and moderate photodamage * subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation. * subjects must be willing to provide verbal understanding and written informed consent. exclusion criteria: * subjects which had a health condition and/or pre-existent dormant dermatological disease on the face * subjects that had any invasive or non-invasive skin treatments, or invasive medical procedures three months prior to the study * subjects that are unwilling to comply with the protocol * female subjects who are pregnant, breast feeding, or planning a pregnancy. * subjects who have any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin, including rosacea, acne, and excessively oily or dry skin. * subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products. * subjects use of any medications that are known to potentially cause changes in the facial skin as determined by the investigator. * subjects who spend excessive time out in the sun.
low versus high dose magnesium sulfate in the early management of rapid atrial fibrillation

Conditions: Atrial Fibrillation

Summary: objective: to assess the efficacy and the safety of high (9g) and low dose (4.5g) of mgs in the immediate treatment of rapid af.

introduction: atrial fibrillation (af) is a potentially life-threatening cardiac arrhythmia and a frequent chief complaint in emergency departments (ed). it is an important concern for a substantial proportion of people worldwide. according to the rotterdam study, the prevalence of af among individuals aged between 55 to 59 years is estimated at 1.1 for 1000 persons/year and 20.7 for individuals between 80 and 84 years. given current adult advanced cardiac life support (acls), the immediate clinical objective in rapid af is to achieve ventricular rate control. digoxin, beta blockers and calcium channel antagonists are the most widely used agents for the emergent treatment of rapid af. however, their effect is limited because only half of the patients will acutely respond to the first intention treatment. several studies showed that the magnesium sulfate (mgs) is beneficial in the control of the rate and the rhythm of af. in addition, hypomagnesemia is present among patients having af in 20 to 53% of the cases . the association of hypomagnesemia and af is common after a cardiac surgery and the prophylactic administration of mgs could be useful in post-operative af . the last meta analysis published in 2007 showed that the mgs is as well efficient in rate control (or = 1.96) as in rhythm control (or = 1.60) of af. however most studies included in this meta analysis were conducted on limited number of patients (303 patients included for rate control outcome analysis and 376 for rhythm control). consequently we need further randomized controlled studies to establish definitively the efficacy and the safety of mgs in the early management of rapid af. objective: to assess the efficacy and the safety of high (9g) and low dose (4.5g) of mgs in the immediate treatment of rapid af.

Eligibility criteria:
inclusion criteria: * all patients presenting to ed with rapid af (heart rate \>120 bpm). exclusion criteria: * unstable hemodynamic state. * renal insufficiency (creatinemia\> 180 µmol/l). * allergy to mgs.

Keywords: rapid atrial fibrillation magnesium sulfate cardiac arrhythmia
hepatitis b virus antibody booster program for the production of hepatitis b immune globulin (hbig)

Conditions: Healthy Volunteers

Summary: hepatitis b virus antibody booster program

the purpose of this study is to vaccinate plasmapheresis donors for collection of high titer plasma to be used in the manufacture of hepatitis b immune globulin (hbig).

Eligibility criteria:
inclusion criteria * age 20-55 years. * naïve or previously hepatitis b-vaccinated males or females. * normal and healthy as determined by medical history, physical exam, vital signs and clinical laboratory tests * subject must meet all required/recommended subject suitability criteria that pertain to normal source plasma donors with the following exception: * subjects who previously tested positive for hbsag may be accepted into the anti- hbs program provided they now test negative and meet all other normal donor suitability criteria. * written informed consent. exclusion criteria: * subjects who have received a hepatitis b vaccination in the previous six months. * history of hypersensitivity to yeast or any components of the engerix-b® vaccine * history of hypersensitivity to any hepatitis b-containing vaccine. * use of any investigational product within the past 30 days or during the course of the study. * use of steroids or immunosuppressives during the study period. * received immunosuppressive therapy (including systemic steroids) within 30 days before study entry * subjects who have received cytotoxic therapy (in the previous 5 years prior to study entry) * received parenteral immune globulin products or blood products within 3 months before study entry with the following exceptions: * rhogam (or equivalent anti-d immune globulin) within 6 weeks before study entry; * pertussis immune globulin: no exclusion * received parenteral immune globulin products or blood products (within 3 months before study entry) * past, present, or suspected iv drug use * positive hiv, hbv\* or hcv test result (\*except as described above in inclusion criteria) * autoimmune disease (such as, but not limited to demyelinating disease) * subjects with cancer, heart disease (including hospitalization for myocardial infarction, arrhythmia, syncope, congestive heart failure), uncontrolled hypertension, uncontrolled insulin-dependent diabetes mellitus, seizures, kidney disease * severely or morbidly obese, or higher obesity classification, which corresponds to bmi of 35 or higher * pregnancy or lactation.
impact of elimination or reduction of dietary animal proteins on cancer progression and survival - a pilot study

Conditions: Neoplasms

Summary: the purposes of this study are * to test the hypothesis that elimination or reduction of dietary animal proteins leads to an improved prognosis in tumor patients * to estimate the effect size and thus to enable sample size calculations for further studies * to test the feasibility and tolerance of different diets, especially a vegan diet, in cancer patients and to proof that a vegan diet does not lead to a deterioration of health, tumor progression or to malnutrition * to test the online platform as a study platform * to test validity of self reported and online generated data

participating cancer patients select one of 3 defined diets (omnivor/lacto-ovo-vegetarian/vegan) at baseline and will continue their prescribed oncological therapy at their attending physician/clinic. participants provide data (cancer history, tumor behavior, food frequency questionnaires, questionnaires referring to quality-of-life) at baseline and at 3 and 6 months with optional data entry points at 12 and 124 months and a follow up questionnaire at 12 and 24 months. data is entered online via the study platforms www.essenundkrebs.net and www.foodandcancer.net in german and english language (no additional clinical visits are required).

Eligibility criteria:
inclusion criteria: * diagnosis of cancer * inclusion in a tumor treatment or follow-up program * age \>18 years exclusion criteria: * psychiatric treatment during the last 3 months * pregnancy * breast feeding * bmi \< 18,5 kg/m2 * major difficulties with food intake (swallowing, lack of appetite) limiting food intake * participation in other studies requiring the attendance to a particular diet

Keywords: vegan diet lacto-ovo-vegetarian diet cancer tumor remission
the effect of regional anesthesia techniques on brain tissue oxygenation in thoracic surgery

Conditions: Thoracic Surgery; Epidural Anesthesia; Cerebral Oxygen Saturation

Summary: today, it is preferred that the lung with pathology for thorax surgery is not under ventilation during operation in terms of reliability and ease of operation. for this reason, the anesthesia approach is characteristic and it is ensured that the single lung is not ventilated during the operation by means of specially manufactured intubation tubes. this application can disrupt tissue oxygenation due to both operation position and single lung ventilation. thoracic epidural analgesia, which is applied as the gold standard of thoracic surgery, is applied prior to the operation and is provided to assist in postoperative analgesia.

the aim of this study was to investigate the effect of thoracic epidural analgesia method on brain tissue oxygenation in patients with single lung ventilation.

Eligibility criteria:
inclusion criteria: * patients who were in the american society of anesthesiologists (asa) i-iii class * underwent thoracic surgery exclusion criteria: * local anesthetic allergy, * bleeding is a diathesis disorder * allergic to the drugs used, * patients who are not reluctant to participate in the study, * presence of infection in the block area, * patients whose body mass index is over 30
the association between thyroid hormones and metabolic components in patients with obesity

Conditions: Obesity; Euthyroid Condition; Metabolic Syndrome

Summary: this study collected clinical data of obese patients with euthyroid function, including age, gender, height, weight, bmi, waist circumference, blood pressure, fasting blood sugar, blood sugar 2 hours after sugar load, fasting plasma high-density lipoprotein cholesterol, fasting three acyl glycerin, free iodine thyroid hormone (ft3) and free thyroid hormones (ft4), thyroid stimulating hormone (tsh), follow-up information and etc. via analyzing the data, the investigators want to investigate the association between thyroid hormones (ths) and metabolic components in obese patients with euthyroid function and to present the cutoff values of ths in order to provide new information for the risk stratification of metabolic syndrome in obese patients with euthyroid function.


Eligibility criteria:
inclusion criteria: * 1) age ranged from 18-65 years old, 2) bmi over 27.9kg/m2,3)tsh，ft4, and ft3 within the range of 0.38-4.34miu/l, 10.5-24.4miu/l, and 2.8-6.3miu/l, respectively. exclusion criteria: * secondary cause of obesity such as hypothalamic obesity, cushing syndrome, and hypophysis dysfunction, etc.,2)pregnancy or location, 3) severe heart, liver and kidney dysfunction